Clorox Co (NYSE:CLX) has earned an average rating of “Hold” from the seventeen research firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $130.70.

Several equities research analysts have recently commented on the company. ValuEngine upgraded Clorox from a “hold” rating to a “buy” rating in a research note on Saturday. Atlantic Securities assumed coverage on Clorox in a research note on Thursday. They set a “neutral” rating and a $151.00 price target for the company. BMO Capital Markets restated a “buy” rating and set a $153.00 price target on shares of Clorox in a research note on Friday, August 3rd. Goldman Sachs Group cut Clorox from a “neutral” rating to a “sell” rating and cut their price target for the stock from $127.00 to $112.00 in a research note on Tuesday, July 17th. They noted that the move was a valuation call. Finally, Bank of America upped their price target on Clorox from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Monday, July 16th.

In other Clorox news, EVP Jon M. Balousek sold 3,354 shares of the stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $144.73, for a total value of $485,424.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael R. Costello sold 9,265 shares of the stock in a transaction on Monday, August 13th. The stock was sold at an average price of $140.02, for a total value of $1,297,285.30. Following the completion of the transaction, the senior vice president now owns 34,293 shares of the company’s stock, valued at approximately $4,801,705.86. The disclosure for this sale can be found here. Insiders sold 29,268 shares of company stock valued at $4,196,686 in the last quarter. 1.00% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in CLX. Parnassus Investments CA increased its position in shares of Clorox by 1.6% in the second quarter. Parnassus Investments CA now owns 4,711,970 shares of the company’s stock valued at $637,294,000 after buying an additional 76,149 shares in the last quarter. Northern Trust Corp increased its position in shares of Clorox by 1.2% in the first quarter. Northern Trust Corp now owns 2,615,416 shares of the company’s stock valued at $348,137,000 after buying an additional 31,461 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Clorox by 437,400.0% in the second quarter. Macquarie Group Ltd. now owns 1,750,000 shares of the company’s stock valued at $236,688,000 after buying an additional 1,749,600 shares in the last quarter. Valueinvest Asset Management S.A. increased its position in shares of Clorox by 2.1% in the first quarter. Valueinvest Asset Management S.A. now owns 1,642,800 shares of the company’s stock valued at $218,673,000 after buying an additional 33,300 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in shares of Clorox by 57.0% in the second quarter. Schroder Investment Management Group now owns 1,506,358 shares of the company’s stock valued at $201,641,000 after buying an additional 547,070 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Shares of CLX stock traded up $0.59 during trading hours on Friday, hitting $152.47. The stock had a trading volume of 1,163,306 shares, compared to its average volume of 761,998. The company has a market capitalization of $19.53 billion, a P/E ratio of 24.36, a PEG ratio of 3.16 and a beta of 0.35. Clorox has a twelve month low of $113.57 and a twelve month high of $153.38. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 3.15.

Clorox (NYSE:CLX) last released its quarterly earnings results on Thursday, August 2nd. The company reported $1.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.08. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.72 billion. During the same quarter in the prior year, the business earned $1.53 earnings per share. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. research analysts predict that Clorox will post 6.41 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 16th. Shareholders of record on Wednesday, October 31st will be given a $0.96 dividend. This represents a $3.84 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Tuesday, October 30th. Clorox’s payout ratio is 61.34%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Story: Day Trading – Risk Worth the Reward?

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.